POSIMIR Market

“POSIMIR Market Size, Forecast, and Drug Insight – 2032” report provides comprehensive insights about POSIMIR for Postoperative Pain and Acute Pain in the United States. A detailed picture of the POSIMIR in the United States for the study period 2019–2032 is provided in this report along with a detailed description of the POSIMIR. The report provides insight about POSIMIR mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the POSIMIR market forecast, analysis in the United States, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies.

POSIMIR Drug Summary

POSIMIR (bupivacaine solution) for infiltration use is a novel and proprietary product that combines the strength of 660 mg of bupivacaine base with the innovative SABER platform technology, enabling continuous, sustained delivery of a non-opioid local analgesic over 3 days in adults. POSIMIR contains more bupivacaine than any other approved single-dose sustained-release bupivacaine product. POSIMIR is administered into the subacromial space under direct arthroscopic visualization at the end of the surgery, where it continuously releases bupivacaine for 72 hours or more. DURECT is in discussions with potential partners regarding the licensing of commercialization rights to POSIMIR, for which DURECT holds worldwide rights.

POSIMIR Market Forecast Report Scope

The report provides insights into:

• A comprehensive product overview including the description, POSIMIR mechanism of action, dosage and administration, research and development activities in Postoperative pain and acute pain.
• Elaborated details on POSIMIR regulatory milestones and other development activities have been provided in this report.
• The POSIMIR Market Size Report also highlights the POSIMIR research and development activity in Postoperative pain and acute pain in detail across the United States.
• The POSIMIR Market Size Report also covers the patents information with expiry timeline around POSIMIR.
• The report contains forecasted POSIMIR Sales for Postoperative pain and acute pain till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Postoperative pain and acute pain.
• The POSIMIR Market Forecast Report also features the SWOT analysis with analyst views for POSIMIR in Postoperative pain and acute pain.

POSIMIR Methodology

The POSIMIR Market Size Report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and POSIMIR Sales Data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

POSIMIR Market Analytical Perspective by DelveInsight

In-depth POSIMIR Market Assessment

This POSIMIR Market Size report provides a detailed market assessment of POSIMIR in Postoperative pain and acute pain in the United States. This segment of the report provides forecasted POSIMIR Sales Data from 2023 to 2032.

POSIMIR Clinical Trials Assessment

The report provides the POSIMIR Clinical Trials information of POSIMIR in Postoperative pain and acute pain covering trial interventions, trial conditions, POSIMIR Clinical Trials status, start and completion dates.

POSIMIR Market Report Highlights

• In the coming years, the market scenario for Postoperative pain and acute pain is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug POSIMIR manufacturers to penetrate more into the market. 
• The POSIMIR Companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence POSIMIR dominance.
• Other emerging products for Postoperative pain and acute pain are expected to give tough market competition to POSIMIR and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of POSIMIR in Postoperative pain and acute pain.
• Our in-depth analysis of the forecasted POSIMIR Sales from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the POSIMIR in Postoperative pain and acute pain.
• Analyze POSIMIR Cost, pricing trends, and market positioning to support strategic decision-making in the Pridopidine Market Landscape.

Key Questions

• What is the product type, route of administration and POSIMIR Mechanism of Action?
• What is the POSIMIR Clinical Trials status of the study related to Postoperative pain and acute pain and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the POSIMIR development?
• What are the key designations that have been granted to POSIMIR for Postoperative pain and acute pain?
• What is the forecasted market scenario of POSIMIR for Postoperative pain and acute pain?
• What are the forecasted POSIMIR Sales in the United States?
• What are the other emerging POSIMIR products available in Postoperative pain and acute pain and how are they giving competition to POSIMIR for Postoperative pain and acute pain?
• Which are the late-stage emerging therapies under development for the treatment of Postoperative pain and acute pain?

Stay updated with us for Recent Articles @ Latest DelveInsight Blogs